1C12

1C12 is a chimeric monoclonal antibody (IgG1) with a human Fc fragment that targets platelet factor 4 (PF4) and PF4-glycosaminoglycan (GAG) complexes. Developed by B Cell Design, 1C12 was originally designed to mimic the pathogenic autoantibodies found in patients with autoimmune heparin-induced thrombocytopenia (aHIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT). It is widely utilized as a research tool and diagnostic calibrator/positive control in external quality assessment programs for HIT testing. Additionally, preclinical research has investigated Fc-inactivated versions of 1C12 as a potential therapeutic strategy to limit PF4-dependent cardiac fibrosis by inhibiting the differentiation of cardiac fibroblasts into myofibroblasts.

Other names

anti-PF4 monoclonal antibody 1C12anti-PF-4 monoclonal antibody 1C12anti-PF 4 monoclonal antibody 1C12chimeric monoclonal anti-PF4 antibody 1C12clone 1C12clone1C12clone-1C12